Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol FYN contributors: mct/npt/pgu - updated : 17-08-2016
HGNC name FYN oncogene related to SRC, FGR, YES
HGNC id 4037
TYPE functioning gene
STRUCTURE 212.14 kb     14 Exon(s)
10 Kb 5' upstream gene genomic sequence study
MAPPING cloned Y linked N status confirmed
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
14 - 2650 60 537 - 2010 19733625
  • a 14 exons variant
  • lacking exons 4 and 11
  • encoding for the longest product
  • 11 splicing 2073 60 534 - 2010 19733625
  • an 11 exons variant
  • lacking exons 1, 2, 3 and 4
  • 11 splicing 2000 54.4 482 - 2010 19733625
  • a 11 exons variant
  • lacking exons 1, 2, 3, 10 and 11
  • encoding for the shortest product
    Type widely
       expressed in (based on citations)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Digestivepharynx   moderately
    Endocrinethyroid   highly
    Lymphoid/Immunespleen   highly
     thymus   moderately
    Nervousbrain   moderately
     nerve   moderately
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Connectiveadipose  highly
    SystemCellPubmedSpeciesStageRna symbol
    cell lineage
    cell lines
    at STAGE
    physiological period embryo
    Text embryonic tissue
  • a Src homolgy 2, a Src homology 3 domains
  • a K homology (KH) motif bound to a QUA2 motif (RNA binding)
  • a proteine kinase catalytic domain
    interspecies homolog to rattus Fyn (99.63 pc)
    homolog to murine Fyn (94.19 pc)
  • Src-family tyrosine kinases
  • Tyr protein kinase family
  • SRC subfamily (signal transduction)
  • STAR (signal transduction and activator of RNA) family
  • CATEGORY enzyme , protooncogene
    SUBCELLULAR LOCALIZATION     plasma membrane
    basic FUNCTION
  • non receptor tyrosine kinase, involved in T cell signaling regulation
  • also involved in protocadherin signaling
  • monopalmitoylated SFK required for VEGF mitogenic signaling with SRC and FYN, but maintaining distinct properties in the regulation of VEGF-mediated endothelial cell events
  • implicated in both brain development and adult brain function
  • in mast cell degranulation in interacting with both cytosolic and structural proteins
  • involved in mast cell degranulation in interacting with both cytosolic and structural proteins
  • may play an important role in HTR6- mediated signaling pathways in the central nervous system
  • involved in tyrosine phosphorylation of KIRREL (results in significantly increased KIRREL and TJP1 binding, suggesting a critical role for KIRREL tyrosine phosphorylation in reorganizing the KIRREL-TJP1 complex)
  • mediates chronic myelogenous leukemia cell proliferation
  • in part through its effects on DAB1, regulates the phosphorylation, trafficking, and processing of APP and LRP8
  • playing a role in exit from meiotic and mitotic metaphases and required for regulation of microtubules polymerization and spindle stabilization
  • play an essential role in signaling events that implicate spindle assembly checkpoint pathway and hence in regulating the exit from metaphase in oocytes and zygote
  • plays a key role in oligodendrocyte differentiation and myelination in the central nervous system
  • FYN cooperates with oncogenic FLT3-ITD in cellular transformation by selective activation of the STAT5 pathway
  • MAGI2 and FYN protect DDN from NEDD4L-mediated ubiquitination and from nuclear translocation, thereby maintaining the physiologic homeostasis of podocytes, and the lack of MAGI2 in podocytes results in glomerulosclerosis
  • CELLULAR PROCESS cell life, proliferation/growth
    signaling signal transduction
    a component
    small molecule metal binding, nucleotide,
  • ATP
  • Mn2+
  • protein
  • the cytoplasmic tail of protocadherins
  • ADD2 (colocalizing under plasma membranes)
  • binding to vimentin and pyruvate kinase
  • complexed with staurosporine
  • ARHGAP33 is a novel FYN substrate
  • interacting with brain-specific PTPRT (PTPRT regulates synapse formation through interaction with cell adhesion molecules, and this function and the phosphatase activity are attenuated through tyrosine phosphorylation by the synaptic tyrosine kinase FYN)
  • PTPRA is an important positive regulator of FYN activation and signaling that is required for the differentiation of oligodendrocyte progenitor cells (OPCs)
  • interaction with FYB, a FYN adapter protein expressed in podocytes, and TMEM47 possibly through FYB, may regulate FYN activity
  • SLIT2 regulates the dispersal of oligodendrocyte precursor cells through FYN and RHOA signaling
  • NCK1 directly modulates NPHS1 phosphorylation through formation of a signaling complex with the Src family kinase FYN
  • functional interaction between FYN, AGAP2, and STAT5A in mediating adipogenesis
  • UNC119 plays a key role in the FYN signal transduction pathway, which regulates the completion of cytokinesis via RAB11A
  • dynamic interaction between CAMK2D2 and FYN in VSM (Vascular smooth muscle) cells, indicating a mechanism by which CAMK2D2 and FYN may coordinately regulate VSM cell motility
  • SH2D1a plays an essential role in collagen-induced arthritis (CIA) because of FYN-independent and FYN-dependent effects on follicular T helper (TFH) cells and, possibly, other T cell types
  • DDN is phosphorylated by FYN and dephosphorylated by PTPN1, and FYN-induced phosphorylation prevents NEDD4L-mediated ubiquitination of dendrin
  • FYN has likely a regulatory role in NOS2 expression in astrocytes during neuroinflammatory responses
  • cell & other
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral       gain of function
    activated in clear cell renal carcinoma with good outcome
    tumoral     --over  
    in chronic myelogenous leukemia blast crisis compared with chronic phase
    Variant & Polymorphism
    Candidate gene
    Therapy target therapies targeting Fyn expression for chronic myelogenous leukemia